A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.

@article{Feighner2000ADP,
  title={A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.},
  author={John P. Feighner and Rudolph H. Ehrensing and Abba J. Kastin and Brian E. Leonard and Lev S Sverdlov and Gabriela Valente Nicolau and Anita Patel and Joseph J. Hlavka and Henry Baxter Abajian and John Fowler Noble},
  journal={Journal of affective disorders},
  year={2000},
  volume={61 1-2},
  pages={
          119-26
        }
}
BACKGROUND INN 00835 is a synthetic pentapeptide with a potential for rapid onset of action as an antidepressant. Its efficacy was investigated in a pilot study in patients diagnosed with major depression. METHODS Fifty two patients received either active drug - INN 00835 (26 patients) - or placebo (26 patients), subcutaneously at 0.2 mg/kg for 5 consecutive days. The patients were evaluated for an additional 4 weeks after treatment. Efficacy was evaluated by the following psychiatric rating… CONTINUE READING
BETA